In the tropical forests of Southeast Asia, farm workers have long chewed the glossy leaves of Mitragyna speciosa to push through heat, pain and exhaustion, relying on a plant that can act as both stimulant and sedative depending on the dose. Today, that same tree — better known as kratom — sits at the center of an American policy debate that spans neuroscience labs, emergency rooms and federal regulatory offices.
At low doses, kratom can make users feel alert and energized, an effect that traditional users in Malaysia and Thailand have used to endure long days of manual labor. At moderate doses, its leaves or teas can blunt pain and ease the aches of physical work, while very high doses can bring on nausea and vomiting before tipping into a euphoric calm reminiscent of opioid painkillers. The plant, a member of the coffee family Rubiaceae, has been used for centuries in parts of Southeast Asia for pain relief, to soften the blow of opium or heroin withdrawal, and simply to get through the day, long before it drew the attention of Western medicine and drug regulators.
In the United States, kratom’s popularity has surged over the past decade in parallel with the opioid crisis, as some people with chronic pain or opioid dependence seek alternatives to prescription pills or illicit heroin. The U.S. National Institute on Drug Abuse notes that kratom products can produce “opioid- and stimulant-like effects,” yet remain legal and readily available in many states, often sold as powders, capsules or concentrated extracts through smoke shops and online vendors (National Institute on Drug Abuse). That legal gray zone, combined with inconsistent product quality and limited clinical evidence, has left researchers racing to understand what this complex plant actually does in the body.
The pharmacology of kratom turns on its rich mixture of alkaloids — naturally occurring nitrogen-containing compounds — at least 37 of which have been identified in the leaves. Two stand out as especially important: mitragynine, the most abundant alkaloid, and 7‑hydroxymitragynine, or 7‑OHMG, a more potent oxidized relative found at lower natural concentrations. Both compounds interact with the same opioid receptors in the brain that respond to drugs like morphine and heroin, but they do so in unusual ways that have intrigued scientists searching for safer painkillers.
Opioid receptors come in three main subtypes — mu, kappa and delta — each named for the drugs that first revealed them. The mu receptor, closely associated with morphine’s powerful pain relief and high overdose risk, has been a central focus of opioid science for decades. Mitragynine and 7‑OHMG act as partial agonists at this mu receptor, which means they bind and activate it but do not fully switch it on the way morphine does. In laboratory experiments, researchers have shown that these kratom alkaloids also appear to avoid a particular downstream signaling pathway involving a protein called beta‑arrestin, which is thought to be tied to the life‑threatening respiratory depression that can accompany high‑dose opioid use.
This signaling nuance may help explain why kratom, at least in anecdotal reports and preclinical studies, appears to pose a lower risk of suppressing breathing than traditional opioids, even while it can ease pain and curb withdrawal. Heroin and high‑dose morphine kill primarily by slowing respiration until breathing stops; that effect can be reversed in emergencies by naloxone, an opioid receptor antagonist marketed as Narcan, which displaces opioids from their receptors. By contrast, kratom’s partial activation of mu receptors and lack of beta‑arrestin recruitment could offer what one researcher has described as a “buprenorphine light” profile, referring to the clinically used medication buprenorphine that has a ceiling effect on respiratory depression.
Kratom’s pharmacology is not limited to the mu receptor. In vitro studies suggest that mitragynine and 7‑OHMG also antagonize kappa and delta opioid receptors, essentially blocking their activity rather than activating them. Kappa agonists are often associated with dysphoria and unpleasant psychological effects, while delta receptors play roles in mood and tolerance. The combined pattern — partial mu agonism with kappa and delta antagonism — has led scientists to speculate that kratom may produce less euphoria and slower tolerance buildup than classical opioids, although these hypotheses still need to be tested in rigorous human trials.
Behind these receptor diagrams lies a long, largely forgotten history of pharmacological investigation. Mitragynine was first isolated from kratom leaves in 1921 by University of Edinburgh chemist Ellen Field, and its structure was later solved in the 1960s via X‑ray crystallography. Around the same time in London, researchers at Chelsea College, including pharmacognosists Joseph Shellard and colleagues, were busy cataloging and characterizing Mitragyna alkaloids. There was early interest from pharmaceutical firms in developing mitragynine as a painkiller that might rival codeine, but toxicity findings in animal studies — notably in beagle dogs — derailed commercial enthusiasm and pushed kratom research back into a niche corner of natural products chemistry.
For decades, the main barrier to progress was simple scarcity: chemists could isolate only milligram quantities of individual alkaloids at a time, far too little for pharmacologists who wanted gram‑level supplies for animal testing. The result was a field rich in structural insights but thin on physiological data. That dynamic began to change in the 2000s, as improved extraction techniques, growing global interest in kratom and rising opioid concerns in the U.S. combined to re‑ignite scientific and regulatory scrutiny.
One of the clearest areas of concern has been product adulteration and variability. In its raw, traditional form, kratom is consumed as fresh leaves or simple teas. In U.S. markets, however, it is often sold as concentrated powders, capsules or liquid extracts whose alkaloid profiles can differ sharply from the plant material. A small study in the Journal of Medical Toxicology found that some commercial kratom products contained significantly elevated levels of 7‑OHMG compared with natural leaf material, raising the possibility that manufacturers were “spiking” products with more potent alkaloid fractions. Such practices could increase the risk of dependence or adverse reactions while leaving consumers with no way to verify what they are actually ingesting.
Regulators have also flagged emerging safety signals. An analysis published in the U.S. Centers for Disease Control and Prevention’s Morbidity and Mortality Weekly Report documented 660 kratom-related calls to poison control centers between 2010 and 2015, with a tenfold increase in annual calls over that period and 49 cases classified as major or life‑threatening (CDC MMWR). Separately, researchers at Nationwide Children’s Hospital have reported more than 1,800 calls to U.S. poison centers about kratom exposures between 2011 and 2017, with sharp increases in the final two years of that window (Nationwide Children’s Hospital). While many of these cases involved mild or moderate symptoms, they underline how kratom has moved from obscurity into mainstream use — and how little is known about the risks when it is combined with other drugs.
So far, kratom has rarely appeared as the sole cause of death in toxicology reports, but it has featured in a handful of fatal mixtures. In Sweden, at least nine deaths were linked to a product marketed as “krypton,” a blend of kratom and an active metabolite of the prescription painkiller tramadol. Other cases have involved combinations of kratom with benzodiazepines, alcohol or antidepressants. In the absence of standardized manufacturing and labeling, emergency physicians say it can be difficult to disentangle the specific contribution of kratom from the broader pattern of polysubstance use in these incidents.
Against this backdrop, the U.S. Drug Enforcement Administration jolted the kratom world in 2016 when it announced plans to place mitragynine and 7‑OHMG in Schedule I of the Controlled Substances Act, alongside heroin and LSD. Schedule I status signifies both high abuse potential and “no currently accepted medical use,” and it imposes some of the tightest restrictions on research access. The proposal triggered an unprecedented wave of public comments, including organized campaigns from the American Kratom Association and detailed analyses from scientists who argued that an outright ban could push users toward far more dangerous opioids and stifle promising research into kratom‑derived analgesics. In an unusual move, the DEA withdrew its notice and asked the U.S. Food and Drug Administration to conduct a formal eight‑factor analysis of kratom’s risks and benefits.
Under federal law, this eight‑factor analysis — which examines pharmacology, abuse potential, public health risks, dependence liability and other scientific criteria — provides the primary basis for scheduling decisions (U.S. Food and Drug Administration). Independent researchers have since published their own eight‑factor assessments, arguing that while kratom has clear psychoactive effects and dependence potential, available evidence does not support classifying it alongside the most dangerous controlled substances (Frontiers in Pharmacology). For now, kratom exists in a kind of regulatory limbo: legal at the federal level, restricted or banned in a patchwork of states and counties, and subject to ongoing import alerts and warning letters from the FDA targeting specific products.
Even as policymakers wrestle with how to categorize kratom, scientists are probing its potential as a template for next-generation pain medicines. In recent years, medicinal chemists have modified the mitragynine scaffold to produce analogs such as mitragynine pseudoindoxyl, which in mouse models appears to be significantly more potent than morphine as an analgesic while producing less respiratory depression and showing no obvious signs of abuse potential. These experimental compounds try to preserve beneficial mu receptor signaling while minimizing beta‑arrestin recruitment and other pathways thought to drive dangerous side effects.
Other research teams are using rodent models of self‑administration to tease apart the roles of different kratom alkaloids in reinforcement and relapse. In one such experiment, rats trained to press a lever for morphine infusions failed to do so when mitragynine was substituted, suggesting limited reinforcing effects, but readily self‑administered 7‑OHMG. When morphine was reintroduced after a period of 7‑OHMG exposure, the animals increased their morphine intake, raising concerns that certain high‑potency preparations could, paradoxically, prime users for heavier opioid use rather than weaning them away from it.
Beyond the lab, survey data hint at who is using kratom and why. A large online survey of more than 8,000 self‑reported kratom users, conducted with the help of advocacy groups, found that the majority cited self‑treatment of pain, anxiety, depression or opioid withdrawal as their primary motivation, and that fewer than 1 percent reported serious adverse effects requiring medical care. While such surveys carry obvious limitations — they capture only self‑selected respondents and cannot confirm doses or product composition — they add nuance to a public conversation that often swings between alarm and advocacy.
Federal health agencies have taken a cautious, often critical stance. The FDA has warned consumers not to use kratom, citing concerns about contamination, unproven health claims and the potential for abuse, and has overseen recalls of salmonella-contaminated kratom products (FDA and Kratom). The agency emphasizes that kratom is not an approved treatment for any medical condition and has moved against companies marketing kratom as a cure for opioid addiction or other serious diseases. At the same time, the National Institutes of Health has funded basic research into kratom’s pharmacology, reflecting a recognition that more data are needed before sweeping policy decisions are made.
In clinical practice, attitudes appear to be slowly shifting from reflexive dismissal toward cautious engagement. In one large survey, roughly 40 percent of kratom users said they had disclosed their use to a health care provider, suggesting that the topic is increasingly surfacing in exam rooms. Some physicians, faced with patients who have already turned to kratom to manage chronic pain or taper off opioids, opt for a harm‑reduction approach: monitoring for interactions, warning about product variability and emphasizing the importance of not combining kratom with other sedatives, rather than insisting on immediate cessation in every case.
The unresolved question hovering over the field is whether kratom is best understood as a botanical supplement, a proto‑drug platform or a public health threat. If its key alkaloids are purified and developed into pharmaceuticals, they will fall under the familiar regime of prescription controls, clinical trials and post‑marketing surveillance. If kratom remains in the looser world of herbal products, regulators may instead pursue frameworks more akin to those used for caffeine, where raw materials are widely accessible but limits are placed on concentrations in finished products and clear labeling is required on dosing and risks. For now, the U.S. Food and Drug Administration, state legislatures and international bodies are still weighing how far to go.
What is clear is that kratom’s strange leaves have opened a window onto both the possibilities and the perils of plant-based psychoactives in an era of mass opioid dependence. The same properties that make kratom attractive to a worker in rural Malaysia — the ability to ward off fatigue, relieve pain and soften withdrawal — now drive its popularity in American communities grappling with overdose and chronic pain. As researchers refine their understanding of mitragynine, 7‑OHMG and their many alkaloid cousins, kratom is likely to remain a flashpoint in the broader debate over how societies respond to drugs that straddle the line between medicine and menace.